Evidence has correlated up-regulation of STAT1 activity with increased breast tumor progression and immune suppression in tumor microenvironment, thus STAT1 inhibition is a promising immune therapeutic target (Hix et al., 2013). This evidence concerns the gene STAT1 and neoplasm.